Skip to Content

5,543 Results Found

  • Review
  • Open Access
21 Citations
10,090 Views
15 Pages

Alzheimer’s disease (AD) impacts more than half a million people worldwide, with no cure available. The regulatory approval of three anti-amyloid monoclonal antibodies (mAbs), including aducanumab, lecanemab, and donanemab, has established immu...

(This article belongs to the Special Issue New Insights in Antibody Therapy)
  • Review
  • Open Access
3 Citations
2,222 Views
18 Pages

The limited efficacy of cytotoxic chemotherapy in the context of gastric cancer treatment is largely driven by profound molecular and biological heterogeneity. In contrast, the development of antibody-mediated therapies has ushered in a new era of pr...

(This article belongs to the Special Issue Gastrointestinal Cancers: From Pathogenesis to Treatment)
  • Review
  • Open Access
152 Citations
20,769 Views
25 Pages

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors

  • Jim Middelburg,
  • Kristel Kemper,
  • Patrick Engelberts,
  • Aran F. Labrijn and ,
  • Janine Schuurman and
  • Thorbald van Hall
  • + 1 author+ 0 author

14 January 2021

Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles,...

(This article belongs to the Special Issue Challenges and Opportunities for Effective Cancer Immunotherapies)
  • Review
  • Open Access
34 Citations
11,676 Views
20 Pages

12 March 2025

The antibody, linker, and payload moieties all play a significant role in giving the ADC its unique therapeutic potential. The antibody subclass employed in ADCs is determined based on relative individual receptor affinities and pharmacokinetics. Mea...

(This article belongs to the Section Cancer Drug Development)
  • Review
  • Open Access
38 Citations
7,709 Views
24 Pages

Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers

  • Kyusang Hwang,
  • Jin Hwan Yoon,
  • Ji Hyun Lee and
  • Sukmook Lee

Colorectal cancer (CRC) is one of the leading causes of cancer deaths worldwide. Recent advances in recombinant DNA technology have led to the development of numerous therapeutic antibodies as major sources of blockbuster drugs for CRC therapy. Simul...

(This article belongs to the Special Issue Colorectal Cancer: From Pathophysiology to Novel Therapeutic Approaches)
  • Review
  • Open Access
22 Citations
6,025 Views
17 Pages

Antibody Conjugates for Sarcoma Therapy: How Far along Are We?

  • Letizia Polito,
  • Giulia Calafato,
  • Massimo Bortolotti,
  • Cecilia Chiarelli Olivari and ,
  • Stefania Maiello and
  • Andrea Bolognesi
  • + 1 author+ 0 author

Sarcomas are one of the most difficult type of cancer to manage and treat because of their extremely heterogeneous molecular and morphological features. Despite the progress made over the years in the establishment of standard protocols for high and...

(This article belongs to the Special Issue Antibody Based Delivery of Toxins and Other Active Molecules for Cancer Therapy)
  • Review
  • Open Access
11 Citations
7,497 Views
19 Pages

6 February 2018

The discovery of highly active antiretroviral therapy (HAART) in 1996 has significantly reduced the global mortality and morbidity caused by the acquired immunodeficiency syndrome (AIDS). However, the therapeutic strategy of HAART that targets multip...

  • Review
  • Open Access
32 Citations
5,971 Views
13 Pages

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates

  • Víctor Albarrán,
  • Diana Isabel Rosero,
  • Jesús Chamorro,
  • Javier Pozas and ,
  • María San Román,
  • Ana María Barrill,
  • Víctor Alía,
  • Pilar Sotoca,
  • Patricia Guerrero and
  • Pablo Gajate
  • + 8 authors+ 3 authors

21 October 2022

Metastatic urothelial cancer, associated with a poor prognosis, is still major cause of cancer-related death, with scarce options of effective treatment after progression to platinum-based chemotherapy and immunotherapy. The human epithelial growth f...

(This article belongs to the Special Issue Bladder Cancer: Molecular Advances in Pathology, Diagnostics, and Therapeutics)
  • Review
  • Open Access
154 Citations
16,195 Views
25 Pages

A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy

  • Deok-Hoon Kong,
  • Mi Ra Kim,
  • Ji Hye Jang,
  • Hee-Jun Na and
  • Sukmook Lee

Tumor angiogenesis is a key event that governs tumor progression and metastasis. It is controlled by the complicated and coordinated actions of pro-angiogenic factors and their receptors that become upregulated during tumorigenesis. Over the past sev...

(This article belongs to the Special Issue Angiogenesis and Anti-Angiogenesis in Oncology: From Bench to Translational Research and Bedside Investigation)
  • Review
  • Open Access
17 Citations
4,819 Views
19 Pages

Melanoma is highly aggressive and is known to be efficient at resisting drug-induced apoptotic signals. Resection is currently the gold standard for melanoma management, but it only offers local control of the early stage of the disease. Metastatic m...

(This article belongs to the Special Issue Nanobiomaterials: From Fundamentals to Biomedical Applications)
  • Review
  • Open Access
7 Citations
13,677 Views
15 Pages

Targeting IgE and Th2-Cytokines in Allergy: Brief Updates on Monoclonal Antibodies and Antibody Gene Therapy

  • Henry C. Ezechukwu,
  • Oyelola A. Adegboye,
  • Wahab O. Okunowo and
  • Theophilus I. Emeto

3 April 2023

The search for an effective treatment of allergic conditions is an ongoing global health challenge due to the high prevalence of allergies. Epinephrine and glucocorticosteroids remain the oldest and most widely used treatment regimen for allergy, and...

(This article belongs to the Section Physiopathology)
  • Review
  • Open Access
270 Citations
31,121 Views
23 Pages

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy

  • Juliana T. W. Tong,
  • Paul W. R. Harris,
  • Margaret A. Brimble and
  • Iman Kavianinia

27 September 2021

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market ‘boom’, garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identificat...

(This article belongs to the Special Issue Advances in Anticancer Drug Discovery II)
  • Review
  • Open Access
19 Citations
16,097 Views
31 Pages

Potential Therapeutic Targets for Combination Antibody Therapy against Pseudomonas aeruginosa Infections

  • Luke L. Proctor,
  • Whitney L. Ward,
  • Conner S. Roggy,
  • Alexandra G. Koontz and ,
  • Katie M. Clark,
  • Alyssa P. Quinn,
  • Meredith Schroeder,
  • Amanda E. Brooks,
  • James M. Small and
  • Benjamin D. Brooks
  • + 6 authors+ 1 author

14 December 2021

Despite advances in antimicrobial therapy and even the advent of some effective vaccines, Pseudomonas aeruginosa (P. aeruginosa) remains a significant cause of infectious disease, primarily due to antibiotic resistance. Although P. aeruginosa is comm...

(This article belongs to the Topic Novel Antimicrobial Agents: Discovery, Design and New Therapeutic Strategies)
  • Review
  • Open Access
8 Citations
6,129 Views
13 Pages

17 September 2024

The disease of transthyretin (TTR) amyloidosis (ATTR) has been known since the 1960s, and during the past 60 or so years, there has been a sustained period of steady discoveries that have led to the current model of ATTR pathogenesis. More recent res...

(This article belongs to the Special Issue Amyloid Composition and Structure-Based Development of Therapeutic and Diagnostic Agents)
  • Review
  • Open Access
24 Citations
8,167 Views
16 Pages

11 January 2023

Monoclonal antibodies are a promising treatment for COVID-19. However, the emergence of SARS-CoV-2 variants raised concerns about these therapies’ efficacy and long-term viability. Studies reported several antibodies, that received authorizatio...

(This article belongs to the Special Issue The Role of Antibodies in SARS-CoV-2 Infection)
  • Communication
  • Open Access
3,497 Views
7 Pages

Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital

  • Judith Pannier,
  • Norbert Nass,
  • Mohamad-Kamal Yaakoub,
  • Florian Michael Maria Stelzner and ,
  • Susann Veit,
  • Margarita Kalomoiri,
  • Mahdi Yassine and
  • Gerhard Behre
  • + 3 authors+ 0 author

20 February 2023

Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infection. Although large clinical trials have been successfully conducted, real world data are needed to obtain a realistic assessment of the assumed effect...

(This article belongs to the Section Viral Infections)
  • Review
  • Open Access
49 Citations
13,660 Views
15 Pages

26 February 2024

Many patients with inflammatory bowel disease (IBD) experience a loss of effectiveness to biologic therapy (i.e., anti-TNF therapy, etc.). Therefore, in addition to the adverse effects of the treatment, these patients also face failure to achieve and...

  • Article
  • Open Access
6 Citations
4,371 Views
12 Pages

Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome

  • Satoshi Yamashita,
  • Atsushi Sakamoto,
  • Satoshi Shoji,
  • Yoshitaka Kawaguchi and ,
  • Yasushi Wakabayashi,
  • Masaki Matsunaga,
  • Kiyohisa Suguro,
  • Yuji Matsumoto,
  • Hiroyuki Takase and
  • Yuichiro Maekawa
  • + 18 authors+ 13 authors

Background: The guideline-recommended low-density lipoprotein cholesterol target level of <70 mg/dL may not be achieved with statin administration in some patients with acute coronary syndrome (ACS). Therefore, the proprotein convertase subtilisin...

(This article belongs to the Special Issue Cardiovascular Risk Factors: Focus on Epidemiology and Clinical Consequences)
  • Review
  • Open Access
20 Citations
10,218 Views
45 Pages

Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads

  • Giovanni Tonon,
  • Flavio Rizzolio,
  • Fabiano Visentin and
  • Thomas Scattolin

This review highlights significant advancements in antibody–drug conjugates (ADCs) equipped with metal-based and nature-inspired payloads, focusing on synthetic strategies for antibody conjugation. Traditional methods such us maleimide and succ...

(This article belongs to the Special Issue Natural Compounds in Cancer Therapy and Prevention, 2nd Edition)
  • Article
  • Open Access
1 Citations
3,090 Views
12 Pages

COVID-19 Antibody Seroconversion in Cancer Patients: Impact of Therapy Cessation—A Single-Center Study

  • Lina Souan,
  • Hikmat Abdel-Razeq,
  • Sura Nashwan,
  • Sara Al Badr and ,
  • Kamal Alrabi and
  • Maher A. Sughayer
  • + 1 author+ 0 author

30 October 2023

Background: The effective development of COVID-19 vaccination has mitigated its harm. Using two laboratory methods, we investigated the efficacy of the BNT162b2 mRNA and BBIBP-CorV COVID-19 vaccines on seroconversion rates in cancer patients undergoi...

(This article belongs to the Special Issue Recent Vaccine Development for Emerging Infectious Diseases)
  • Review
  • Open Access
42 Citations
11,768 Views
41 Pages

11 July 2022

In the past 25 years, a considerable number of therapeutic monoclonal antibodies (mAb) against a variety of tumor-associated antigens (TAA) have become available for the targeted treatment of hematologic and solid cancers. Such antibodies opsonize ca...

(This article belongs to the Special Issue Tumor-Associated Myeloid Cells)
  • Review
  • Open Access
38 Citations
12,836 Views
19 Pages

17 March 2021

Glucose-regulated protein 94 (GRP94) is an endoplasmic reticulum (ER)-resident member of the heat shock protein 90 (HSP90) family. In physiological conditions, it plays a vital role in regulating biological functions, including chaperoning cellular p...

(This article belongs to the Special Issue Molecular Chaperones: Cancer and Cell Death)
  • Feature Paper
  • Article
  • Open Access
17 Citations
4,078 Views
13 Pages

A Boron Delivery Antibody (BDA) with Boronated Specific Residues: New Perspectives in Boron Neutron Capture Therapy from an In Silico Investigation

  • Alessandro Rondina,
  • Paola Fossa,
  • Alessandro Orro,
  • Luciano Milanesi and ,
  • Antonella De Palma,
  • Davide Perico,
  • Pier Luigi Mauri and
  • Pasqualina D’Ursi
  • + 3 authors+ 0 author

18 November 2021

Boron Neutron Capture Therapy (BNCT) is a tumor cell-selective radiotherapy based on a nuclear reaction that occurs when the isotope boron-10 (10B) is radiated by low-energy thermal neutrons or epithermal neutrons, triggering a nuclear fission respon...

(This article belongs to the Section Cellular Biophysics)
  • Article
  • Open Access
20 Citations
5,337 Views
18 Pages

Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma

  • Satoshi Kamoto,
  • Masahiro Shinada,
  • Daiki Kato,
  • Sho Yoshimoto and ,
  • Namiko Ikeda,
  • Masaya Tsuboi,
  • Ryohei Yoshitake,
  • Shotaro Eto,
  • Yuko Hashimoto and
  • Takayuki Nakagawa
  • + 12 authors+ 7 authors

23 November 2020

Podoplanin (PDPN), a small transmembrane mucin-like glycoprotein, is ectopically expressed on tumor cells. PDPN is known to be linked with several aspects of tumor malignancies in certain types of human and canine tumors. Therefore, it is considered...

(This article belongs to the Special Issue Structure and Function of Podoplanin (PDPN) in Disease)
  • Review
  • Open Access
8 Citations
3,593 Views
28 Pages

Precision Antibody Therapy in Gastric and Gastroesophageal Cancer: Targeting FGFR2b, CLDN18.2, and VEGFR2

  • Vivian Chetachi Eziefula Njoku,
  • Yein Lee,
  • Joytish Ramesh,
  • Peter Kubatka and
  • Dietrich Büsselberg

26 October 2025

Gastric and gastroesophageal junction (G/GEJ) adenocarcinomas remain among the most aggressive and lethal malignancies globally. Most patients are diagnosed at advanced stages and respond poorly to conventional chemotherapy, highlighting the urgent d...

  • Article
  • Open Access
32 Citations
9,839 Views
14 Pages

Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers

  • Yingnan Si,
  • Ya Zhang,
  • Jia-Shiung Guan,
  • Hanh Giai Ngo and ,
  • Angela Totoro,
  • Ajeet Pal Singh,
  • Kai Chen,
  • Yuanxin Xu,
  • Eddy S. Yang and
  • Xiaoguang (Margaret) Liu
  • + 7 authors+ 2 authors

10 August 2021

Triple-negative breast cancers (TNBCs) are frequently recurrent due to the development of drug resistance post chemotherapy. Both the existing literature and our study found that surface receptor CD47 (cluster of differentiation 47) was upregulated i...

(This article belongs to the Collection Research on Monoclonal Antibodies and Antibody Engineering)
  • Article
  • Open Access
42 Citations
10,314 Views
15 Pages

A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology

  • Hao-Kang Li,
  • Ching-Wen Hsiao,
  • Sen-Han Yang,
  • Hsiu-Ping Yang and ,
  • Tai-Sheng Wu,
  • Chia-Yun Lee,
  • Yan-Liang Lin,
  • Janet Pan,
  • Zih-Fei Cheng and
  • Sai-Wen Tang
  • + 7 authors+ 2 authors

31 May 2021

Natural killer (NK) cells harbor efficient cytotoxicity against tumor cells without causing life-threatening cytokine release syndrome (CRS) or graft-versus-host disease (GvHD). When compared to chimeric antigen receptor (CAR) technology, Antibody-Ce...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
10 Citations
6,250 Views
10 Pages

28 April 2015

Antibody directed enzyme prodrug therapy (ADEPT) utilizing β-lactamase is a promising treatment strategy to enhance the therapeutic effect and safety of cytotoxic agents. In this method, a conjugate (antibody-β-lactamase fusion protein) is employed...

(This article belongs to the Section Biochemistry)
  • Article
  • Open Access
6 Citations
2,792 Views
12 Pages

7 January 2022

Background and Objectives: The present study aims to analyze the complex patient/treating physician interaction at onset of botulinum toxin (BoNT) therapy in patients with idiopathic cervical dystonia (CD) and the influence of high initial doses on l...

  • Article
  • Open Access
297 Views
19 Pages

Background/Objectives: Antigen-specific adoptive CD8+ T-cell therapy has demonstrated promising clinical activity in selected cancers; however, its broader efficacy against solid tumors remains limited by the immunosuppressive tumor microenvironment...

(This article belongs to the Section Immunology and Immunotherapy)
  • Review
  • Open Access
20 Citations
7,154 Views
33 Pages

Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies

  • Evi B. Struble,
  • Jonathan M. O. Rawson,
  • Tzanko Stantchev,
  • Dorothy Scott and
  • Marjorie A. Shapiro

Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment...

(This article belongs to the Special Issue Drugs for Antiviral Combination Therapy)
  • Article
  • Open Access
35 Citations
10,043 Views
18 Pages

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy

  • Marion Adelfinger,
  • Simon Bessler,
  • Alexa Frentzen,
  • Alexander Cecil and ,
  • Johanna Langbein-Laugwitz,
  • Ivaylo Gentschev and
  • Aladar A. Szalay
  • + 2 authors+ 0 author

20 July 2015

Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a novel approach for canine cancer therapy. Here we describe, for the first time, the characterization and the use of VACV strain GLV-5b451 expressing the anti-vascular endothelia...

(This article belongs to the Special Issue Oncolytic Viruses)
  • Review
  • Open Access
15 Citations
11,601 Views
12 Pages

Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies

  • Zhiqing Zhang,
  • Shaowei Li,
  • Ying Gu and
  • Ningshao Xia

18 November 2016

Human immunodeficiency virus type 1 (HIV-1) infection causes acquired immune deficiency syndrome (AIDS), a global epidemic for more than three decades. HIV-1 replication is primarily controlled through antiretroviral therapy (ART) but this treatment...

(This article belongs to the Special Issue Immuno- and Neuropathogenesis of HIV Disease: Mechanisms, Prevention, Treatment, and Cure)
  • Article
  • Open Access
4 Citations
2,150 Views
12 Pages

Background: The present study aimed to evaluate and compare the efficacy and safety of anti-programmed cell death protein 1 (anti-PD-1) antibody plus lenvatinib (tyrosine kinase inhibitor) therapy and chemotherapy as the first-line treatment to unres...

(This article belongs to the Special Issue Advanced Cancer Diagnosis and Treatment)
  • Review
  • Open Access
158 Citations
27,289 Views
31 Pages

26 February 2020

The ability of monoclonal antibodies to specifically bind a target antigen and neutralize or stimulate its activity is the basis for the rapid growth and development of the therapeutic antibody field. In recent years, traditional immunoglobulin antib...

(This article belongs to the Special Issue Advances in Antibody Therapy of Cancer)
  • Article
  • Open Access
175 Views
29 Pages

23 October 2026

Background: Cancer diagnoses among women of reproductive age are increasing alongside trends toward delayed childbearing. Managing cancer while addressing fertility preservation, pregnancy, and lactation presents complex, drug-specific challenges tha...

(This article belongs to the Special Issue Advances in Pregnancy: From Risk Prediction to Precision Epidemiology)
  • Systematic Review
  • Open Access
11 Citations
5,563 Views
22 Pages

Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials

  • Matteo Gallina,
  • Anna Carollo,
  • Anna Gallina,
  • Sofia Cutaia and ,
  • Sergio Rizzo and
  • Alessio Provenzani
  • + 1 author+ 0 author

Background/Objectives: Lung cancer is the leading cause of cancer-related deaths worldwide. Non-Small-Cell Lung Cancer (NSCLC) accounts for 80–90% of all lung cancers. Antibody-Drug Conjugates (ADCs) represent an expanding targeted therapy opti...

(This article belongs to the Section Clinical Pharmaceutics)
  • Review
  • Open Access
53 Citations
10,346 Views
31 Pages

Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats

  • Brent A. Williams,
  • Arjun Law,
  • Judit Hunyadkurti,
  • Stephanie Desilets and ,
  • Jeffrey V. Leyton and
  • Armand Keating
  • + 1 author+ 0 author

20 August 2019

In recent decades, therapy for acute myeloid leukemia (AML) has remained relatively unchanged, with chemotherapy regimens primarily consisting of an induction regimen based on a daunorubicin and cytarabine backbone, followed by consolidation chemothe...

(This article belongs to the Special Issue Immunotherapies for Acute Myeloid Leukemia)
  • Communication
  • Open Access
25 Citations
3,295 Views
6 Pages

Do Anti-Phage Antibodies Persist after Phage Therapy? A Preliminary Report

  • Marzanna Łusiak-Szelachowska,
  • Ryszard Międzybrodzki,
  • Paweł Rogóż,
  • Beata Weber-Dąbrowska and ,
  • Maciej Żaczek and
  • Andrzej Górski
  • + 1 author+ 0 author

5 October 2022

Phages are immunogenic and may evoke an immune response following their administration. Consequently, patients undergoing phage therapy (PT) produce phage-neutralizing serum antibodies. The clinical significance of this phenomenon for the success or...

(This article belongs to the Section Bacteriophages)
  • Review
  • Open Access
96 Citations
17,742 Views
17 Pages

Antibody–Drug Conjugates for Cancer Therapy

  • Adam C. Parslow,
  • Sagun Parakh,
  • Fook-Thean Lee,
  • Hui K. Gan and
  • Andrew M. Scott

Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient...

(This article belongs to the Special Issue Development, Manufacture and Clinical Application of Drug Conjugates in Cancer Therapy)
  • Review
  • Open Access
216 Citations
23,551 Views
22 Pages

Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications

  • Nirnoy Dan,
  • Saini Setua,
  • Vivek K. Kashyap,
  • Sheema Khan and ,
  • Meena Jaggi,
  • Murali M. Yallapu and
  • Subhash C. Chauhan
  • + 2 authors+ 0 author

Chemotherapy is one of the major therapeutic options for cancer treatment. Chemotherapy is often associated with a low therapeutic window due to its poor specificity towards tumor cells/tissues. Antibody-drug conjugate (ADC) technology may provide a...

(This article belongs to the Special Issue Anticancer Drugs)
  • Review
  • Open Access
13 Citations
6,278 Views
23 Pages

Targeted Alpha Therapy (TAT) with Single-Domain Antibodies (Nanobodies)

  • Kate Hurley,
  • Meiyun Cao,
  • Haiming Huang and
  • Yi Wang

4 July 2023

The persistent threat of cancer necessitates the development of improved and more efficient therapeutic strategies that limit damage to healthy tissues. Targeted alpha therapy (TαT), a novel form of radioimmuno-therapy (RIT), utilizes a targeti...

(This article belongs to the Special Issue Cell Signaling in Cancer and Cancer Therapy)
  • Review
  • Open Access
39 Citations
11,209 Views
34 Pages

Monoclonal Antibody Therapy in Alzheimer’s Disease

  • Monica Neațu,
  • Anca Covaliu,
  • Iulia Ioniță,
  • Ana Jugurt and ,
  • Eugenia Irene Davidescu and
  • Bogdan Ovidiu Popescu
  • + 1 author+ 0 author

Alzheimer’s disease is a neurodegenerative condition marked by the progressive deterioration of cognitive abilities, memory impairment, and the accumulation of abnormal proteins, specifically beta-amyloid plaques and tau tangles, within the bra...

(This article belongs to the Section Clinical Pharmaceutics)
  • Review
  • Open Access
9 Citations
5,511 Views
23 Pages

29 April 2025

Cancer remains one of the leading causes of mortality worldwide, with a growing need for precise and effective treatments. Traditional therapies such as chemotherapy and radiotherapy have limitations, including off-target effects and drug resistance....

(This article belongs to the Special Issue Advances in Cellular and Molecular Mechanisms in Immuno-Oncology and Onco-Hematology)
  • Review
  • Open Access
18 Citations
8,913 Views
19 Pages

Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies?

  • Xiaofeng Jiang,
  • Ling Sun,
  • Chengwu Hu,
  • Feijian Zheng and ,
  • Zhengbing Lyu and
  • Jianzhong Shao
  • + 1 author+ 0 author

16 September 2023

Antibodies represent a relatively mature detection means and serve as therapeutic drug carriers in the clinical diagnosis and treatment of cancer—among which monoclonal antibodies (mAbs) currently occupy a dominant position. However, the emerge...

(This article belongs to the Special Issue Marine Natural Products as Anticancer Agents 3.0)
  • Review
  • Open Access
6 Citations
2,116 Views
21 Pages

17 February 2025

Antibody therapies are a crucial component of modern lymphoid malignancy treatment and an exciting area of active research. We performed a review of modern antibody therapies used in the treatment of lymphoid malignancies, with an emphasis on landmar...

(This article belongs to the Special Issue Antibody Therapy for Hematologic Malignancies)
  • Review
  • Open Access
75 Citations
22,528 Views
31 Pages

25 October 2017

Developing therapeutics that induce apoptosis in cancer cells has become an increasingly attractive approach for the past 30 years. The discovery of tumor necrosis factor (TNF) superfamily members and more specifically TNF-related apoptosis-inducing...

  • Review
  • Open Access
492 Views
27 Pages

Antibody-Mediated Therapies in Urothelial Carcinoma: A Critical Narrative Review

  • Se-Il Go,
  • Viozzy Florendinha da Costa Xavier,
  • Myoung Hee Kang and
  • Won Sup Lee

24 August 2026

Urothelial carcinoma (UCC) remains a clinical challenge due to its high recurrence rate and aggressive advanced-stage behavior. Driven by a high tumor mutational burden and the consistent overexpression of surface antigens, including Nectin-4, Trop-2...

(This article belongs to the Topic Antibody-Mediated Therapy and Other Emerging Therapies in Cancer Treatment)
  • Review
  • Open Access
17 Citations
5,420 Views
25 Pages

Potential Therapeutic Targets for Combination Antibody Therapy Against Staphylococcus aureus Infections

  • Sharon Ke,
  • Hyein Kil,
  • Conner Roggy,
  • Ty Shields and ,
  • Zachary Quinn,
  • Alyssa P. Quinn,
  • James M. Small,
  • Francina D. Towne,
  • Amanda E. Brooks and
  • Benjamin D. Brooks
  • + 5 authors+ 0 author

5 November 2024

Despite the significant advances in antibiotic treatments and therapeutics, Staphylococcus aureus (S. aureus) remains a formidable pathogen, primarily due to its rapid acquisition of antibiotic resistance. Known for its array of virulence factors, in...

  • Review
  • Open Access
1 Citations
1,159 Views
45 Pages

8 June 2026

Non-Hodgkin lymphoma (NHL) encompasses a biologically diverse group of malignancies for which the integration of precision medicine has markedly reshaped therapeutic strategies. Recent advances in molecular profiling, target identification, and drug...

(This article belongs to the Special Issue Therapeutic Advances in Hematological Malignancies: New Breakthroughs and Future Directions)

of 111